Open AccessKidney-Related Outcome in Cardiorenal Syndrome Type 3
Author(s) -
Kim Drubel,
Benedikt Marahrens,
Oliver Ritter,
Daniel Patschan
Publication year - 2022
Publication title -
international journal of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.551
H-Index - 29
eISSN - 2090-2158
pISSN - 2090-214X
DOI - 10.1155/2022/4895434
Subject(s) - medicine , cardiorenal syndrome , dialysis , renal function , acute kidney injury , clinical endpoint , single center , observational study , retrospective cohort study , intensive care medicine , pediatrics , clinical trial
Background and Aim. In cardiorenal syndrome (CRS) type 3, acute kidney injury (AKI) induces and, sometimes, even perpetuates acute cardiac pathologies such as arrhythmias with or without cardiac decompensation or the latter due to other causes. Epidemiological data on CRS type 3 are limited. The aim of this study was to analyze epidemiological and outcome variables in CRS type 3. Methods. A single-center, retrospective and observational trial. All subjects with positive AKI alert, treated at the University Hospital Brandenburg between January and December 2019, were evaluated. Definition of CRS type 3 was according to predefined criteria. The three endpoint categories were in-hospital death, dialysis, and recovery of kidney function. Results. A total number of 1,334 AKI alerts were screened. Finally, 95 subjects received the diagnosis CRS type 3. The survival rates were 47.1% (females) and 43.6% (males). 46.8% of affected females and 33.3% of the males required dialysis therapy. Complete recovery at the time of discharge occurred in 35.8%, and no recovery at all was found in 54.7%. Conclusions. All three predefined study endpoints, the mortality, the prevalence of dialysis, and the percentage of subjects without recovery of kidney function, were notably high. Therefore, AKI patients with imminent or established cardiac complications require the highest attention of nephrologists in charge.